The global capivasertib market size was estimated at USD 485.7 million in 2025 and is predicted to increase from USD 584.78 million in 2026 to approximately USD 3109.09 million by 2035, expanding at a CAGR of 21.05% from 2026 to 2035. The globe is facing a burden of diverse cancer cases, like breast cancer and prostate cancer, which propels demand for advanced targeted therapies, like capivasertib. Alongside, researchers are encouraging the development of combination therapies with capivasertib to improve efficacy in these instances.
The use of a targeted oral drug to treat particular kinds of advanced or metastatic breast cancer is defined as the capivasertib market. The global expansion is majorly fueled by the rising incidence of PIK3CA/AKT1/PTEN alterations in metastatic breast cancer, which propels demand for specific AKT inhibitors. Another key growth factor of the market is the recent FDA approval for Truqap (capivasertib) in combination with fulvestrant, which provides a significant novel treatment line, & finally raises growth-free survival.
A prominent application of AI algorithms includes the analysis of tumor samples to find PIK3CA, AKT1, & PTEN pathway changes, which further supports detecting patient eligibility for capivasertib therapy. Besides this, modern AI models foster the identification of patients with predicted results from the combination of capivasertib & fulvestrant, specifically in instances resistant to aromatase inhibitors (AIs).
Emerging FDA & Global Approvals
Along with positive results from the Phase III CAPItello-291 trial, capivasertib acquired regulatory approval in many regions, such as the US & the UK, for HR+/HER2- metastatic breast cancer with specific biomarker alterations.
Spurring Biomarker-Selected Populations
A major trend is shifting towards tailored medicine, where treatment is restricted to patients with PIK3CA/AKT1/PTEN alterations.
Focus on Prostate & Other Solid Tumors
Prospective efforts will encourage the evaluation of capivasertib for hormone-sensitive metastatic prostate cancer in the CAPItello-281 trial & in castration-resistant prostate cancer in the CAPItello-280 trial.
| Table | Scope |
| Market Size in 2026 | USD 584.78 Million |
| Projected Market Size in 2035 | USD 3109.09 Million |
| CAGR (2026 - 2035) | 21.05% |
| Leading Region | North America by 44% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Indication, By Therapy Type, By Route of Administration, By End User, By Biomarker Type, By Distribution Channel, By Line of Treatment, By Region |
| Top Key Players | AstraZeneca, Astex Therapeutics, MSD, Daiichi Sankyo, The Institute of Cancer Research, Cancer Research Technology Limited, Sun Pharmaceutical Industries Ltd., Novartis, Gilead Sciences, Inc., Eisai Co., Ltd. |
| Segment | Share 2025 (%) |
| Breast Cancer | 58% |
| Prostate Cancer | 16% |
| Ovarian Cancer | 9% |
| Endometrial Cancer | 7% |
| Other Solid Tumors | 10% |
The Breast Cancer Segment Dominated the Market in 2025
The breast cancer segment captured a major share of 58.00% of the capivasertib market in 2025. A vital catalyst is 2.3 million cases of breast cancer per year, with a higher frequency of PIK3CA, AKT1, & PTEN pathway alterations. Immersive, consistent clinical trials are employing capivasertib for expanded TNBC. The latest studies have combined capivasertib with fulvestrant, resulting in improved PFS compared with placebo.
The prostate cancer segment held the second-largest share of a 16.00% in 2025 & is predicted to expand rapidly. The segmental growth is driven by surging trials in mCRPC, with growing demand for biomarker-guided treatment, which elevates adoption rates. The era has explored a combination of capivasertib (Truqap) & abiraterone, with androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC)
The ovarian cancer segment captured a 9.00% share of the capivasertib market, due to the rising need for targeted therapies in recurrent ovarian cancer cases. Specifically, in the cases of resistance to treatment with platinum-based chemotherapy, capivasertib has a pivotal role in resolving this resistance.
Whereas the endometrial cancer segment accounted for a notable share of 7.00% in 2025. Drivers are accelerating the prevalence of endometrial malignancies, which raises demand for advanced treatment, and a focus on personalized oncology spurs integration of targeted therapy.
| Segment | Share 2025 (%) |
| Monotherapy | 31% |
| Combination Therapy | 69% |
The Combination Therapy Segment Led the Market in 2025
In 2025, the combination therapy segment held a 69.00% share in 2025 & is estimated to show rapid expansion in the capivasertib market. This approach offers progression-free survival in expanded cancers. Also, these therapies have a substantial efficacy in patients with specific alterations in the PI3K/AKT pathway. This kind facilitates a novel alternative for patients who have already been administered endocrine therapy.
However, the monotherapy segment captured a 31.00% of the market in 2025, due to the convenience of oral targeted therapy, which assists standalone application in selected patients. Also, this has minimal toxicity with enhanced treatment adherence, coupled with early approvals to maintain baseline demand.
| Segment | Share 2025 (%) |
| Oral | 82% |
| Hospital-administered Combination Regimens | 18% |
The Oral Segment Was Dominant in the Market in 2025
The oral segment led with a 82.00% share of the market in 2025 & is estimated to grow fastest in the capivasertib market. Dominance is fueled by a home-based approach, which lowers hospitalization needs, with an easy-to-swallow ROA. Also, it is considered a manageable, long-term maintenance solution, instead of intensive inpatient treatment.
Moreover, the hospital-administered combination regimens segment held a significant share of 18.00% in 2025. Many hospital infrastructures promote complex therapies by leveraging combination infusion protocols, which stay crucial in the latest oncology settings. This ROA needs close monitoring for toxicities, like hyperglycemia & rash, which revealed a manageable safety profile, allowing its adoption in specialized hospital settings.
| Segment | Share 2025 (%) |
| Hospitals | 48% |
| Specialty Cancer Centers | 34% |
| Academic & Research Institutes | 11% |
| Ambulatory Surgical Centers | 7% |
The Hospitals Segment Led the Market in 2025
The hospitals segment accounted for a dominant share of 48.00% of the capivasertib market in 2025. Hospitals offer an extensive management setting for advanced oncology patients. Also, the capivasertib necessitates pre-testing, where hospitals are propelled by an increased adoption of biomarker testing protocols. Alongside, robust clinical evaluation demands a greater uptake among patients confirmed with AKT pathway alterations.
The specialty cancer centers segment held 34% share in 2025 and is anticipated to show the fastest growth. These centers widely provide faster adoption of groundbreaking targeted therapies. Also, they emphasize the development of tailored medicine, which boosts biomarker-based treatment. Many of the oncology centers are broadening their networks to bolster patient access.
The academic & research institutes segment held a 11.00% share in 2025, due to rigorous involvement in clinical trials, which helps therapy assessment. Numerous research funding agencies are encouraging translational oncology studies. Also, they are increasingly joining with pharma firms to transform innovation.
Whereas, the ambulatory surgical centers segment captured a 7.00% share of the capivasertib market in 2025. They offer affordable cancer care models, coupled with a well-established supportive care infrastructure, which raises patient throughput. Also, several outpatient oncology procedures are boosting treatment opportunities across the market.
| Segment | Share 2025 (%) |
| PIK3CA Mutation | 39% |
| AKT Mutation | 28% |
| PTEN Deficiency | 21% |
| Other PI3K/AKT Pathway Alterations | 12% |
The PIK3CA Mutation Segment Dominated the Market in 2025
In 2025, the PIK3CA mutation segment led with a 39.00% share of the market. Dominance is driven by a massive rise in nearly 30–40% of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). This majorly boosts the production of PIP3 by direct activation of AKT, where capivasertib is a pan-AKT inhibitor, serving on AKT1, AKT2, & AKT3 to block this pathway.
The AKT mutation segment captured 28% share and is estimated to expand at a rapid CAGR in the capivasertib market. Expanding genomic testing identifies more AKT-altered tumors. AKT mainly activates E17K substitution in the PH structural site, leading to aberrant signaling & is a vital target for capivasertib, which has shown high sensitivity to these specific mutations.
The PTEN deficiency segment held a notable share of 21.00% of the market, due to they become targets for pathway inhibition. Alongside, combination trials are broadening therapeutic opportunities, coupled with an emphasis on research activities, which bolster understanding of resistance mechanisms.
The other PI3K/AKT pathway alterations segment captured a 12.00% share in the capivasertib market. Their robust identification is impelled by the execution of advanced sequencing technologies. Another catalyst is tumors with mutations in mTOR or loss of TSC1/2, which skips AKT inhibition by activating the downstream mTORC1 complex.
In 2025, North America led with a 44.00% share of the market, due to the extensive oncology drug commercialization which promotes the regional market to become the leader. Also, the region has suitable reimbursement that surges the adoption of targeted therapy. Besides this, the emergence of a robust healthcare system supports the progression of expensive, innovative, targeted treatments. Many firms are widely leveraging biomarker testing to demonstrate patient identification efficiently.
For instance,
U.S. Market Trends
Whereas the U.S. accounted for a dominant share of the capivasertib market, due to the rigorous regulatory approvals. Also, U.S. players are widely emphasizing raising clinical efficiency, resolving cost-effectiveness bottlenecks of the respective therapies.
During the prospective period, the Asia Pacific is anticipated to witness rapid expansion in the market, and the region also held 21.00% of the share in 2025. This will be driven by the huge rise in the burden of cancer cases, which demand advanced treatment solutions. Besides this, continuous government investment in cancer care, excellent diagnostic capabilities, & growth of healthcare access in developing countries, including China & India, are encouraging rapid adoption of novel therapies.
For instance,
China Market Trends
The capivasertib market in China has demonstrated cohort studies, which described a suitable benefit-risk profile regardless of PIK3CA/AKT1/PTEN alteration status, though benefits were specifically robust in those with these alterations. Alongside, China is majorly pushing oncology drug development pipeline, with a focus on novel therapies & rigorous alliances among firms.
R&D
Clinical Trials & Regulatory Approvals
Patient Support & Services
| Companies | Description |
| AstraZeneca | It has rolled out Truqap, a first-in-class, oral AKT inhibitor. |
| Astex Therapeutics | Its offerings cover discovery platforms, commercial agreements, etc. |
| MSD | This firm facilitated an oncology alliance with AstraZeneca to co-develop drugs, including Lynparza & Koselugo. |
| Daiichi Sankyo | A company explores clinical synergies between capivasertib & their own antibody-drug conjugate (ADC) portfolio, especially in breast cancer. |
| The Institute of Cancer Research | This mainly acts as a foundational role in discovering & designing capivasertib. |
| Cancer Research Technology Limited | This provides discovery & synthesis, structure-based designing, preclinical testing, & early clinical development solutions for oncology drugs. |
| Sun Pharmaceutical Industries Ltd. | This company offers clinical research & advanced cancer care. |
| Novartis | A firm provides drugs acting through the AKT pathway inhibition. |
| Gilead Sciences, Inc. | It facilitates diverse Trop-2-directed antibody-drug conjugates & cell therapies. |
| Eisai Co., Ltd. | This is mainly providing its clinical evaluation & regulatory framework within Japan, specifically in combination with other therapies for breast cancer. |
Strengths
Weaknesses
Opportunities
Threats
By Indication
By Therapy Type
By Route of Administration
By End User
By Biomarker Type
By Distribution Channel
By Line of Treatment
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
